Immune escape in the context of malignant progression of glioma has become a hot topic of research for clinical tumor immunotherapy, in which the checkpoint pathway represented by the PD-L1/PD-1 axis is of great significance (31, 33, 34). This evidence concerns the gene CD274 and central nervous system cancer.